230 related articles for article (PubMed ID: 16317734)
1. Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.
Michaels LA; Philipp CS; Eisele J; Pappas H; Saidi P
Pediatr Blood Cancer; 2007 Oct; 49(5):736-9. PubMed ID: 16317734
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.
Mathijssen NC; Masereeuw R; Verbeek K; Lavergne JM; Costa JM; van Heerde WL; Nováková IR
Br J Haematol; 2004 May; 125(4):494-9. PubMed ID: 15142120
[TBL] [Abstract][Full Text] [Related]
3. Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency.
Farah RA; Hamod D; Melick N; Giansily-Blaizot M; Sallah S
J Thromb Haemost; 2007 Feb; 5(2):433-4. PubMed ID: 17109737
[No Abstract] [Full Text] [Related]
4. Use of recombinant factor VIIa for hip surgery in a patient with factor-VII deficiency. A case report.
Gopalan PK; Clohisy JC; Cashen AF; Eby CS
J Bone Joint Surg Am; 2007 Feb; 89(2):389-91. PubMed ID: 17272455
[No Abstract] [Full Text] [Related]
5. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
6. Factor VII deficiency and its treatment in delivery with recombinant factor VII.
Pehlivanov B; Milchev N; Kroumov G
Eur J Obstet Gynecol Reprod Biol; 2004 Oct; 116(2):237-8. PubMed ID: 15358473
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIIa for the treatment of congenital factor VII deficiency.
Hunault M; Bauer KA
Semin Thromb Hemost; 2000; 26(4):401-5. PubMed ID: 11092215
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa, its clinical properties, and the tissue factor pathway of coagulation.
Bosinski TJ; El Solh AA
Mini Rev Med Chem; 2006 Oct; 6(10):1111-7. PubMed ID: 17073711
[TBL] [Abstract][Full Text] [Related]
9. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Mariani G; Konkle BA; Ingerslev J
Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
Mathew P; Young G
Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports.
Cohen LJ; McWilliams NB; Neuberg R; Zinkham W; Bauer K; Gribble TJ; Glowalla MB; Borson R; Phillips MD; Kunschak M
Am J Hematol; 1995 Dec; 50(4):269-76. PubMed ID: 7485101
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Tcheng WY; Donkin J; Konzal S; Wong WY
Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
[TBL] [Abstract][Full Text] [Related]
13. The use of recombinant factor VIIa for bleeding in paediatric practice.
Millar CG; Stringer MD; Sugarman I; Richards M
Haemophilia; 2005 Mar; 11(2):171-4. PubMed ID: 15810920
[TBL] [Abstract][Full Text] [Related]
14. Factor VII deficiency.
Perry DJ
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S47-54. PubMed ID: 14567537
[TBL] [Abstract][Full Text] [Related]
15. Combined deficiency of factors VII and X: clinical description of two cases and management of spinal surgery.
Chilcott JL; Russell G; Mumford AD
Haemophilia; 2006 Sep; 12(5):555-8. PubMed ID: 16919090
[No Abstract] [Full Text] [Related]
16. Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII.
İnce Z; Bulut Ö; Tuğrul-Aksakal M; Ünüvar A; Devecioğlu Ö; Çoban A
Turk J Pediatr; 2018; 60(5):562-565. PubMed ID: 30968639
[TBL] [Abstract][Full Text] [Related]
17. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.
Mathijssen NC; Masereeuw R; Holme PA; van Kraaij MG; Laros-van Gorkom BA; Peyvandi F; van Heerde WL
Thromb Res; 2013 Aug; 132(2):256-62. PubMed ID: 23834817
[TBL] [Abstract][Full Text] [Related]
18. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
Carr ME; Martin EJ; Kuhn JG; Ambrose H; Fern S; Bryant PC
Clin Lab; 2004; 50(9-10):529-38. PubMed ID: 15481628
[TBL] [Abstract][Full Text] [Related]
20. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Weiskopf RB
Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
